Acadia Pharmaceuticals (ACAD) Other Accumulated Expenses (2011 - 2026)

Acadia Pharmaceuticals' Other Accumulated Expenses history runs 16 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 72.49% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (up 72.49% YoY), while the FY2025 annual figure was $5.9 million, up 73.78% from the prior year.
• Other Accumulated Expenses was $16.1 million for Q1 2026 at Acadia Pharmaceuticals, up from $5.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $16.1 million in Q1 2026 to a low of $986000.0 in Q2 2022.
• Historically, Other Accumulated Expenses has averaged $7.8 million across 5 years, with a median of $8.9 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses jumped 777.84% in 2023, then plunged 69.31% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $2.7 million in 2022, then jumped by 307.53% to $11.0 million in 2023, then tumbled by 69.31% to $3.4 million in 2024, then soared by 73.78% to $5.9 million in 2025, then jumped by 173.92% to $16.1 million in 2026.
• The last three Other Accumulated Expenses figures came in at $16.1 million (Q1 2026), $5.9 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.